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Abstract Ischemic stroke is a major cause of morbidity
and mortality for which the only approved treatment in the
acute setting is intravenous thrombolysis. The efficacy and
safety of recombinant tissue plasminogen activator (rt-PA)
have been firmly established within 3 h of symptom onset;
however, few patients are eligible for treatment in this time
window. Expanding the time for treatment has been
challenging, but new evidence has demonstrated a modest
statistical improvement in selected patients when rt-PA is
administered within 4.5 h. This important finding hopefully
will enable more patients to receive treatment and simul-
taneously provides an opportunity to reaffirm that the
benefits of rt-PA diminish with time.
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Introduction
Despite extensive international research efforts, ischemic
stroke remains the third leading cause of death and the most
common cause of disability in industrialized nations [1].
Stroke affects more than half a million people in the United
States every year [2] and will become more prevalent in an
aging society increasingly afflicted with stroke risk factors,
such as obesity, diabetes, and hypertension [3]. Although
potentially debilitating, stroke also is the only neurologic
disorder for which the symptoms may be completely
reversed with appropriate treatment.
For many decades, a nihilistic approach toward stroke
management led physicians away from actively treating
stroke victims. This nihilism was unfortunate but under-
standable because no acute therapy was available to reverse
the disease process. Thrombolytic medications such as
streptokinase have been tested since the 1970s, but out-
comes were consistently unsuccessful because of severe
hemorrhagic complications [4]. In the 1980s, neurologists
began investigating recombinant tissue plasminogen acti-
vator (rt-PA), and in a landmark article published in
Science, Zivin et al. [5] demonstrated promising results
using an embolic model. Further preclinical work estab-
lished the relative safety of rt-PA for embolic stroke,
although possible safety concerns with concomitant anti-
platelet medications would require additional research [6].
The only approved therapy for acute ischemic stroke is
rt-PA [7]. In large community surveys, its use has been
frustratingly low; however, with organized stroke delivery
teams, rates of 10% to 20% can be achieved [8, 9]. There are
many reasons patients do not receive acute treatment, but
one major limitation is the rather short 3-hour time window
used in the pivotal National Institute of Neurological
Disorders and Stroke (NINDS) study [10]. Recently
published randomized trials designed to expand this window
may allow an increase in the number of eligible patients. We
briefly review the historical background for the limited time
window as well as recent studies that encourage an extension
of the therapeutic time window for intravenous thrombolysis.
Preliminary Studies
One of the first randomized controlled trials (RCTs) testing
the efficacy and safety of intravenous rt-PA in human
subjects was the European Cooperative Acute Stroke Study
(ECASS). This was a prospective, multicenter, double-blind,
placebo-controlled clinical trial that randomly assigned
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rt-PA or placebo within 6 h from symptom onset. The
primary outcome measures were the Barthel index and
modified Rankin scale at 90 days. No significant differences
between the groups were identified in the intention-to-treat
analysis; furthermore, the rt-PA group suffered increased
mortality and symptomatic intracranial hemorrhages (sICH).
A target population analysis (removing protocol violations)
favored rt-PA,but the trial ultimately was plagued by protocol
violationsandapoorlyselectedpatientpopulation[11]. When
the subgroup of ECASS patients who were treated within 3 h
was analyzed separately, however, a statistically significant
benefit was found [12]. ECASS differed from the NINDS
study in significant ways, including the important differences
of using a higher dose, less strict blood pressure parameters,
and an extended treatment window; these distinctions may
have accounted for the lack of benefit and increased
hemorrhage rate relative to the NINDS trial.
Learning from ECASS, the ECASS II trial was designed
with a lower dose of rt-PA, also administered within 6 h of
symptom onset. Stricter eligibility criteria included imaging
and blood pressure guidelines, but again, rt-PA did not alter
the primary end point. Similar to the first ECASS trial,
ECASS II showed trends favoring rt-PA, but none was
significant. sICH remained more common in the rt-PA
group, although this difference did not lead to an overall
increase in morbidity or mortality [13].
Simultaneously, another randomized, double-blind, mul-
ticenter, placebo-controlled clinical trial testing rt-PA was
being conducted in the United States. Alteplase Thrombo-
lysis for Acute Noninterventional Therapy in Ischemic
Stroke (ATLANTIS) initially was designed to assess the
efficacy and safety of intravenous rt-PA administered within
6 h of symptom onset, but safety concerns halted enrollment
during the 5- to 6-hour window. The study before that point
was renamed Part A, and going forward, new study patients
enrolled between 0 and 5 h would constitute a separate trial
(Part B). Eventually, ATLANTIS Part B was modified to a 3-
to 5-hour window after the NINDS results were published,
but the study was stopped early because of slow recruitment.
As with ECASS I and II, ATLANTIS could not support the
use of rt-PA in patients treated 3 to 5 h after symptom onset.
Again, rt-PA increased the rate of sICH, but a comparison
with the NINDS study suggested this was not caused by the
increased treatment time.
NINDS
In 1995, the first successful randomized study using rt-PA
in stroke was published. The NINDS study, like ECASS I/II
and ATLANTIS, was a double-blind trial. Unlike prior
studies, NINDS restricted the treatment time to less than 3 h
from symptom onset and reduced the dose of rt-PA to
0.9 mg/kg. Moreover, one half of the patients were treated
within 90 min of symptom onset to maximize the likelihood
of finding a benefit. NINDS consisted of two parts, the first
measuring clinical activity within 24 h of stroke onset and
the second using a global test to assess clinical outcome at
3 months.
In Part 1, no statistically significant differences between
groups were found using the primary outcome measure
(improvement of ≥4 points in National Institutes of Health
Stroke Scale [NIHSS] score or complete resolution of
neurologic deficits). It is worth remembering that the
number of points (4) chosen to determine effectiveness
was essentially a guess based on limited preclinical
information, and post hoc analysis revealed statistically
significant improvement using almost any other NIHSS
improvement criteria or time strata [14]. All secondary
outcome measures used in the first NINDS trial, including
3-month outcome on the modified Rankin scale and Barthel
index, statistically significantly favored rt-PA treatment.
In contrast to the previous trials, NINDS Part 1 was the
only study to use 24-hour improvement as a primary
outcome measure. In retrospect, this could be a shortcom-
ing of the study because it ultimately may not be a relevant
assessment. Final neurologic recovery is most important,
and this cannot be determined accurately at 24 h. Although
3 months may not encompass the full extent of recovery
either, it is much more reflective of eventual outcomes than
the period when acute injury processes are still active.
Regardless of the debate surrounding 24-hour improve-
ment, Part 2 of the NINDS trial assessed clinical results at
3 months as a primary outcome and did reveal statistically
significant differences. Four primary outcomes were
measured (Barthel index, modified Rankin scale, Glasgow
outcome scale, and NIHSS), and the number of patients
with favorable outcomes for each method was greater in
the rt-PA group than in the placebo group. Compared with
placebo, there was a 12% absolute increase and 32%
relative increase in the number of patients with minimal or
no disability among those treated with rt-PA. Importantly,
this benefit was not offset with any increase in mortality.
There were more symptomatic hemorrhages in rt-PA–
treated patients (6.4% vs 0.1%, P<0.001), but these
patients had more severe baseline deficits and the
proportion with hemorrhage was lower than in other RCTs
with rt-PA [10].
The NINDS study demonstrated a clear benefit of rt-PA
when used in the first 3 h, and it was hoped that rt-PA
would become widely used. Licensing bodies granted
approval in the United States (1996), Canada (1999), and
Europe (2002), but widespread adoption of thrombolytic
therapy for acute stroke proceeded slowly as several
challenges emerged.
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cians not experienced in making rapid decisions in stroke
patients were reluctant to administer rt-PA [15]. Intravenous
thrombolytic therapy represented a radical change from the
previous standards of care for ischemic stroke that consisted
largely of supportive therapy. rt-PA offered a high-risk/
high-reward alternative, but therapy often was withheld
because of the fear of causing intracranial hemorrhage.
Further analysis of hemorrhage rates from the NINDS data
subsequently addressed many of these concerns by showing
that the clinically relevant number needed to harm is close
to 1 in 100 [16]. rt-PA now is fully accepted by almost all
neurologists, but debate still exists among emergency
medicine physicians, especially in areas where stroke
specialists are not available to assist in the decision-
making process [17].
At the same time, many patients are excluded from
treatment because they are deemed to have neurologic
deficits too mild or too rapidly improving to warrant the
risks of rt-PA. Two published reports addressed this
issue, and both found an unacceptably high number of
patients (between one in three and one in four) deemed
“t o og o o dt ot r e a t ” on admission who were dead or
dependant at discharge [18, 19]. Decisions about throm-
bolytics in patients with mild symptoms are often difficult,
but it should be remembered that patients with unstable
disease processes can quickly improve before quickly
declining. Such patients remain challenging, but current
literature seems to support thrombolytic treatment [20].
Extending the Time Window
By far the largest obstacle restricting rt-PA in acute stroke
treatment has been the time window [21]. Many patients do
not arrive at the hospital within 3 h, and even then, a
comprehensive effort is required to evaluate a patient, make
a treatment decision, and quickly administer rt-PA. Practi-
cally speaking, a patient must present to a hospital well
before 3 h to have the opportunity to receive rt-PA.
Individual cases require varying amounts of time to arrive
at a treatment decision, but fulfilling clinical and diagnostic
criteria generally takes about 60 min [8]. Up to 20% of
stroke patients receive rt-PA at certified stroke centers
[8, 9], but the overall percentage receiving treatment often
is quoted at less than 5% [22]. Extending the treatment
window clearly would allow more patients to be treated;
however, until recently the NINDS trial was the only
successful rt-PA study, and a series of clinical trials already
failed to broaden the window.
To explore a longer time window, a pooled analysis
from six trials (NINDS Parts 1 and 2, ECASS I and II,
and ATLANTIS Parts A and B) was performed. Despite
minor differences in methodologies (ie, dose of rt-PA and
time to treatment initiation), all studies had similar
protocols, allowing the raw data to be pooled and analyzed,
a more powerful technique than meta-analysis. Evaluating
favorable 3-month outcomes (modified Rankin scale 0–1,
Barthel index 95–100, and NIHSS 0–1) and occurrence of
sICH were the main outcome measures.
As in both parts of the NINDS trial, the pooled analysis
showed that the benefit of rt-PA diminishes as time elapses.
A favorable outcome was most likely to occur in patients
treated within 90 min and declined at every interval
thereafter. Interestingly, the pooled analysis revealed that
the odds ratio for a favorable outcome when treated between
3 and 4.5 h was 1.40 and the adjusted hazard ratio was not
significantly worse at 4.5 h than 3 h. These findings implied
a beneficial effect of rt-PA beyond 3 h but, according to the
same analysis, did not appear to extend to 6 h [23].
When the European Medicines Evaluation Agency
(EMEA) approved rt-PA in 2002, it required two further
studies. The first was to ensure that clinical application was
as safe as that in study conditions, and the second was a
trial extending the time window beyond 3 h.
The Safe Implementation of Thrombolysis in Stroke–
Monitoring Study (SITS-MOST) was created to assess
safety and efficacy by tracking sICH within 24 h and
mortality at 3 months as primary outcomes. It became the
largest stroke thrombolysis database and far exceeded the
requirements of the regulatory authorities. The results
showed that rt-PA in routine practice has a safety profile
as good as or better than that seen in RCTs and is effective
when used within 3 h of stroke onset [24].
The Safe Implementation of Thrombolysis in Stroke–
International Stroke Treatment Registry (SITS-ISTR)
then used a post hoc analysis to compare 11,865
ischemic stroke patients treated with rt-PA under 3 h
with 664 patients treated between 3 and 4.5 h. No
significant differences were found between the groups
with regard to sICH, mortality, or independence at
90 days [25]. SITS-ISTR suggested the therapeutic
window for safe, effective thrombolysis in acute stroke
c o u l db ee x t e n d e db e y o n d3h .
ECASS III
Despite the inability of previous RCTs to prove efficacy
beyond 3 h, SITS-ISTR suggested rt-PA was safe, and the
pooled analysis suggested it was beneficial beyond estab-
lished time windows. Further investigation was warranted,
and by that time, the EMEA’ss e c o n dr e q u i r e ds t u d y —the
randomizedtrialwithatimewindowbeyond3h—hadbegun.
ECASS III initially was created as a randomized,
placebo-controlled, phase 3 trial testing the efficacy and
Curr Neurol Neurosci Rep (2010) 10:29–33 31safety of rt-PA administered 3 to 4 h after symptom onset.
In 2005, based on results from the pooled analysis and slow
recruitment, the study protocol was changed to allow an
expanded time window from 3 to 4.5 h.
ECASS III enrolled 821 patients from 19 European
countries, 418 of whom received rt-PA; of these patients,
10% were treated between 3 and 3.5 h, 46.8% between 3.5
and 4 h, and 39.2% between 4 and 4.5 h. In the rt-PA group,
52.4% of patients achieved favorable outcomes, compared
with 45.2% in the placebo group (absolute improvement of
7.2%, P=0.04), and the global odds ratio resulted in better
outcomes in patients treated with rt-PA. The sICH rate with
rt-PA was higher than with placebo, but overall mortality
was not affected. Comparing sICH among studies is
challenging because of varying definitions, but regardless
of the definition or expanded time window, the rate of sICH
in ECASS III was not higher than previously reported.
ECASS III confirmed the NINDS finding of a signifi-
cant benefit with rt-PA in the primary end point at
3 months. When rt-PA was given 3 to 4.5 h after the
onset of stroke symptoms, a modest but significant
improvement in clinical outcome was revealed. This earlier
time to treatment is probably why ECASS III succeeded
where previous, similarly designed trials did not. As
discussed earlier, the effectiveness of rt-PA diminishes
rapidly with time. Although ECASS I/II and ATLANTIS
tested treatment windows between 3 and 6 h, a dispropor-
tionate number of patients were enrolled just before time
cutoffs. ATLANTIS Part B tested a treatment window from 3
to 5 h after symptom onset, but nearly 80% of patients were
enrolled in the 4- to 5-hour interval and the average time to
treatment for the entire trial was more than 4.5 h. Knowing
that rt-PA’s benefit fades with time, it is not surprising, in
retrospect, that previous trials did not succeed. In contrast,
enrollment in ECASS III was evenly spread throughout the
allowed time window; patients were not clumped near the
end. In fact, the median time to enrollment was a reasonable
3 h and 59 min. ECASS III also selected patients who may
have been more likely to benefit from rt-PA. Although not
supported by the NINDS findings, those with severe stroke
(NIHSS > 25) and a combination of prior stroke and diabetes
were felt to be less likely to benefit and therefore were
excluded from ECASS III [26•]. Finally, other trials simply
did not contain sufficient sample size (power) to detect the
modest (7.2%) benefit seen in ECASS III.
Conclusions
ECASS III is an important step forward in treating stroke
patients.Whereasphysiciansoftenwerehandcuffedbyastrict
3-hour treatment window, now they have 90 extra minutes.
Hopefully, more patients will receive therapy as a result, but
based on the experience after the NINDS trial, time will be
required before physicians feel comfortable with this change.
A recent advisory paper from the American Heart Associa-
tion/American Stroke Association (AHA/ASA) may help; it
concluded that the pooled analysis and ECASS III data
warranted a class I recommendation, level of evidence B, that
rt-PA should be offered between 3 and 4.5 h to select patients.
TreatingpatientswithECASSIIIexclusioncriteria,suchasan
NIHSS score greater than 25, age greater than 80 years, and
therapy with oral anticoagulation (regardless of international
normalized ratio), is not established and, as such, received a
class IIb recommendation, level of evidence C [27•].
ECASS III also serves to confirm the basic finding of the
NINDS trial in an independent population: intravenous
rt-PA treatment powerfully and safely ameliorates disability
after acute ischemic stroke. Although mainstream neurolo-
gists and emergency medicine physicians accepted this
finding long ago, residual skepticism remained in some
quarters, fanned by irresponsible distortions from self-
appointed “expert” naysayers. The replication of the
NINDS trial in ECASS III should lay to rest all remaining
skepticism about intravenous rt-PA for acute stroke.
Some of the most useful lessons from ECASS III
ultimately may be what this study does not mean [28•].
The ideal treatment window is not anytime before 4.5 h,
and physicians cannot use the liberty of 90 extra minutes to
delay treatment decisions. As the ECASS III authors
astutely point out, early treatment remains critical, and the
odds of a favorable outcome decline with every minute. In
the NINDS study, for one patient to have a favorable
outcome, the number needed to treat was 8.4, but in the
extended window of ECASS III, the number needed to treat
rose to 14. Although benefit exists until 4.5 h, the goal must
be to keep the door-to-needle time as short as possible,
generally within 1 h.
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